Financial Performance - For the year ended December 31, 2024, the Group's turnover decreased by approximately 22% to approximately HK$114 million, down from approximately HK$146 million in FY23[16] - The gross profit margin for FY24 was approximately 33%, compared to approximately 41% in FY23[17] - The overall loss attributable to owners of the Company was approximately HK$40 million, a decrease from HK$135 million in the corresponding year[17] - The gross profit decreased to approximately HK$37 million for the Reporting Year versus approximately HK$60 million in FY23, with a gross profit margin decrease to approximately 33% (FY23: 41%) due to realized losses from investments and decreased interest income[84] - The Group recorded a revenue decrease of approximately 22% from approximately HK$146 million for the year ended 31 December 2023 to approximately HK$114 million for the year ended 31 December 2024[82] - For the year ended 31 December 2024, the Group recorded a net loss of approximately HK$40 million, a significant improvement compared to a loss of approximately HK$135 million in FY23[97] Revenue Breakdown - Revenue from the investment in financial instruments segment decreased from a net gain of approximately HK$6 million in FY23 to a net loss of less than HK$1 million in FY24[21] - Revenue from the Chinese health products segment decreased from approximately HK$130 million in FY23 to approximately HK$113 million in FY24[21] - Revenue from the money lending segment decreased from approximately HK$11 million in FY23 to approximately HK$1 million in FY24[21] - The Chinese health products business segment recorded a loss (before taxation) of approximately HK$6 million in FY24, compared to a profit of HK$3 million in FY23[23] - The traditional Chinese medicine health products segment generated revenue of approximately HK$113 million, a decline from HK$130 million in FY23, and reported a segment loss of approximately HK$6 million compared to a profit of HK$3 million in FY23[26] - The money lending business generated interest income of approximately HK$1 million, down from HK$11 million in FY23, with a segment loss of approximately HK$10 million compared to a loss of HK$116 million in FY23[29] Economic Environment - The challenging economic environment and changing consumer spending patterns significantly impacted the Group's revenue during FY24[24] - The decrease in revenue from the traditional Chinese medicine segment was attributed to a challenging economic environment and changing consumer spending patterns[26] - Local retail business is expected to face challenges due to inflation, recruitment difficulties, and rising operational costs[59] - The Chinese health products business faced challenges in FY24, with high-end product sales declining by approximately 10% to 34% year-over-year[57] Loan Receivables and Credit Losses - As of December 31, 2024, approximately HK$300 million of loan receivables were classified as stage 3 (credit-impaired), representing about 97% of the gross outstanding balance of loan receivables[29] - The expected credit loss (ECL) recognized during FY24 was approximately HK$2 million, significantly reduced from HK$107 million in FY23[34] - The total gross balance of loan receivables as of December 31, 2024, was approximately HK$308.7 million, with a net amount of approximately HK$8.6 million after ECL allowance[37] - The accumulated allowance for Expected Credit Loss (ECL) on the Group's loan receivables amounted to approximately HK$300 million, an increase from approximately HK$294 million as of December 31, 2023[41] - As of December 31, 2024, loan receivables classified as stage 3 represented 97% of the total gross loan receivable balances, up from 95% in FY23[93] Operational Changes and Strategies - The Group maintained eleven outstanding loans as of December 31, 2024, with two classified under stage 1 and nine under stage 3[34] - The Group plans to enhance the promotion of ready-to-eat health products and collaborate with MAME LAB to introduce maternal health care products, targeting local and younger consumers[63] - The Group will launch on the Xiaohongshu social platform in partnership with Weimob to engage directly with consumers, particularly in the PRC market[63] - The management team has implemented cost control measures and enhanced overseas sourcing efficiency to remain competitive[59] - The Group's strategy includes diversifying revenue sources through investments and acquisitions of promising businesses or projects[69] Financial Position and Assets - The Group's total current assets as of 31 December 2024 were approximately HK$113 million, down from HK$140 million as of 31 December 2023[76] - The Group's total assets as of December 31, 2024, were approximately HK$122 million, down from HK$150 million as of December 31, 2023[117] - The Group's borrowings increased to approximately HK$33 million as of December 31, 2024, compared to approximately HK$29 million as of December 31, 2023[70] - The Group's cash and bank balances were approximately HK$10 million as of December 31, 2024, down from approximately HK$14 million as of December 31, 2023[70] - The Group recorded a decrease in shareholders' funds from approximately HK$4 million as of December 31, 2023 to a net liabilities position of approximately HK$18 million as of December 31, 2024[76] Governance and Compliance - The Company has complied with all code provisions set out in the Corporate Governance Code throughout the year ended December 31, 2024[154] - The Board has focused on empowering and developing employees to create long-term value and sustainable growth for shareholders[155] - The Board emphasizes the importance of establishing a culture of integrity, responsibility, collaboration, teamwork, and customer focus to achieve the Company's objectives[163] - The Company is committed to attracting, retaining, and developing talented employees as part of its strategic objectives[163] - The Company received annual written confirmations of independence from all Independent Non-executive Directors for the year ended December 31, 2024[197]

Financial Performance - China Healthwise Holdings Limited reported total revenue of HKD 146,317,000 for the year ending December 31, 2024, compared to HKD 113,575,000 for the previous year, representing a year-over-year increase of 29%[2] - The gross profit for the year was HKD 37,349,000, down from HKD 60,294,000 in the previous year, indicating a decrease of 38%[2] - The net loss for the year was HKD 40,281,000, compared to a net loss of HKD 134,558,000 in the previous year, showing an improvement of 70%[2] - The basic and diluted loss per share was HKD 0.092 (9 cents), improved from HKD 0.1746 (17.46 cents) in the previous year[4] - For the fiscal year ending December 31, 2024, the company reported a net loss of approximately HKD 40,428,000[9] - The total segment loss before tax for the year ending December 31, 2024, was HKD 22,621,000, compared to a loss of HKD 118,344,000 in 2023, indicating an improvement in performance[20] - The company reported a pre-tax loss of HKD 79,374 million, a decrease from HKD 70,759 million in the previous year[28] - The group recorded a total loss attributable to shareholders of about HKD 40 million for the reporting year, compared to approximately HKD 135 million in fiscal year 2023[61] Revenue and Income Sources - Revenue from major business operations for the year is detailed, with specific figures for customer contract income and other sources of income[15][16] - Customer contract income for the year was reported at HKD 112,832 thousand, compared to HKD 129,523 thousand in the previous year, indicating a decline[16] - External customer revenue for the year ending December 31, 2024, was HKD 113,575,000, a decrease from HKD 146,317,000 in 2023, representing a decline of approximately 22.3%[20] - Revenue from the investment financial instruments segment decreased from a net income of approximately HKD 6 million in the previous fiscal year to a net loss of less than HKD 1 million in the current fiscal year[43] - Revenue from the traditional Chinese medicine health products segment decreased from approximately HKD 130 million in the previous fiscal year to about HKD 113 million in the current fiscal year[43] - The traditional Chinese medicine health products segment contributed approximately HKD 113 million in revenue and incurred a loss of about HKD 6 million before tax in the current fiscal year[44] Assets and Liabilities - As of December 31, 2024, the company's total liabilities amounted to approximately HKD 18,838,000[9] - The company's current assets increased from HKD 113,250,000 in 2023 to HKD 139,655,000 in 2024, representing a growth of approximately 23.3%[5] - The total assets for the reporting segments decreased from HKD 146,778,000 in 2023 to HKD 119,557,000 in 2024, reflecting a reduction of about 18.6%[22] - The total liabilities for the reporting segments decreased from HKD 145,272,000 in 2023 to HKD 140,426,000 in 2024, showing a decline of approximately 3.9%[22] - The company's current and non-current borrowings were HKD 32,572,000 and HKD 63,330,000, respectively[9] - The company's total liabilities amounted to approximately HKD 18.38 million as of December 31, 2024[40] - The debt-to-asset ratio is approximately 79%, compared to 67% on December 31, 2023[71] Cash Flow and Financial Management - The company is implementing measures to improve cash flow, including recovering receivables and cost-saving initiatives[9] - The company aims to meet its operational funding needs through improved cash flow from operations[9] - The board has reviewed the group's cash flow forecast, which covers a period of not less than twelve months from the end of the reporting period[10] - The group believes it will have sufficient working capital to meet its operational and financial obligations for the next twelve months[10] - The group is considering measures to improve cash flow, including recovering outstanding receivables and controlling operational costs[13] - The group anticipates challenges in the lending business environment due to expected high HKD interest rates in 2025, which may deter potential borrowers[67] - The group will closely monitor customer repayment habits and develop action plans for debt recovery as risks increase[67] Operational Efficiency and Cost Management - The company reported a significant increase in operating expenses, with general and administrative expenses rising to HKD 26,414,000 from HKD 37,529,000, a decrease of 30%[2] - Employee costs, including director remuneration, totaled HKD 28,966,000 for the year, with HKD 19,408,000 attributed to the herbal health product segment[23] - Selling and distribution expenses increased to approximately HKD 29 million, a rise of about 4% compared to the previous fiscal year[57] - General and administrative expenses decreased to approximately HKD 26 million from HKD 38 million in fiscal year 2023, attributed to cost-saving measures implemented during the reporting year[58] - Financing costs amounted to approximately HKD 8 million, down from about HKD 9 million in fiscal year 2023[59] Credit Risk and Impairment - The company reported a net impairment loss on receivables of HKD 107,469 million, indicating significant credit risk exposure[24] - The expected credit loss provision for receivables was HKD 300,087,000 in 2024, compared to HKD 294,218,000 in 2023, reflecting an increase in provisions[34] - The expected credit loss model provisions for impairment losses decreased significantly to about HKD 2 million from approximately HKD 107 million in the previous fiscal year[60] - The group recognized an expected credit loss of approximately HKD 2 million for the fiscal year, a decrease from HKD 107 million in the previous fiscal year[50] Market Conditions and Strategic Initiatives - The company faced a challenging economic environment, particularly in local retail, which negatively impacted revenue due to changing consumer spending patterns[45] - The local retail business is expected to face challenges due to inflation, hiring difficulties, and rising operational costs, prompting the management team to implement cost control measures[64] - The group plans to enhance the promotion of convenient health food products, including various herbal teas and health supplements, targeting local consumers and the younger demographic[65] - The company plans to enhance its market presence through new product development and strategic investments in the herbal health product segment[21] - The group aims to diversify its revenue sources through investments or acquisitions of businesses with broad prospects[69]

| --- | --- | |----------------------------|-------| | | | | Stock Code 股份代號: 00348 | | Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 簡明綜合損益及其他全面收益表 For the six months ended 30 June 2024 截至二零二四年六月三十日止六個月 中國智能健康控股有限公司 二零二四年中期報告 1 For the six months ended 30 June 2024 截至二零二四年六月三十日止六個月 The board of directors (the "Board" or "Directors") of China Healthwise Holdings Limited (the "Company") is pleased to announce the unaudited condensed consolidated results of the Company and ...

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 60,932,000, a decrease of 24.7% compared to HKD 80,826,000 for the same period in 2023[1] - Gross profit for the same period was HKD 19,661,000, down 41.6% from HKD 33,653,000 year-over-year[1] - The net loss for the six months ended June 30, 2024, was HKD 28,663,000, compared to a net loss of HKD 31,862,000 in the prior year, indicating a 6.9% improvement[2] - Basic and diluted loss per share was HKD 3.72 for the six months ended June 30, 2024, compared to HKD 4.14 for the same period in 2023[2] - Customer contract revenue from the sale of traditional Chinese health products was HKD 60.43 million for the six months ended June 30, 2024, down from HKD 70.26 million for the same period in 2023, representing a decrease of approximately 14.5%[11] - Interest income for the six months ended June 30, 2024, was HKD 611,000, a significant decrease from HKD 5.70 million in the same period of 2023[11] - The group reported a segment loss before tax of HKD (22,150) for the six months ended June 30, 2024, compared to a loss of HKD (23,903) for the same period in 2023, indicating a slight improvement[16] - The group recorded a loss attributable to shareholders of approximately HKD 29 million for the current period, compared to a loss of approximately HKD 32 million for the corresponding period[44] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 132,791,000, a decrease from HKD 142,953,000 as of December 31, 2023[3] - Current liabilities decreased to HKD 101,550,000 from HKD 139,655,000 year-over-year, reflecting a reduction of 27.3%[3] - The company’s equity position showed a net deficit of HKD 24,262,000 as of June 30, 2024, compared to a positive equity of HKD 4,398,000 in the previous year[4] - The total liabilities for the group as of June 30, 2024, were HKD 133,698, a decrease from HKD 145,272 as of June 30, 2023, representing a reduction of about 8%[18] - The group’s total current assets decreased from HKD 39,861 million in December 2023 to HKD 35,057 million in June 2024, representing a decline of approximately 12.5%[30] - The group reported a total of HKD 20,535 million in trade payables and other payables as of June 2024, down from HKD 33,427 million in December 2023, indicating a decrease of approximately 38.5%[34] - The group’s borrowings from securities brokers increased from HKD 15,108 million in December 2023 to HKD 18,944 million in June 2024, reflecting an increase of about 25.5%[35] - The group’s other loans amounted to HKD 10,443 million as of June 2024, compared to HKD 13,614 million in December 2023, showing a decrease of approximately 23.5%[36] Cash Flow and Credit Management - The group is implementing measures to improve cash flow, including recovering receivables and cost-saving initiatives[6] - The board has conducted a detailed review of the group's cash flow forecasts, which cover at least the next 12 months[7] - The group is considering the fair value adjustments of financial assets to improve cash flow[6] - The group has recognized a net loss of HKD 105,000 from the sale of financial instruments for the six months ended June 30, 2024[11] - The group’s cash and cash equivalents decreased to HKD 75 as of June 30, 2024, from HKD 992 as of June 30, 2023, indicating a substantial reduction in liquidity[17] - The aging analysis of trade receivables shows that amounts due within 90 days decreased significantly from HKD 5,517 million in December 2023 to HKD 2,311 million in June 2024, a decline of about 58.2%[33] - The expected credit loss provision for accounts receivable was HKD 299,775,000 for the six months ended June 30, 2024, compared to HKD 294,218,000 for the same period in 2023, indicating an increase of 1.9%[29] - The group assessed the recoverability of receivables, confirming an expected credit loss provision of approximately HKD 300 million, which does not impact the group's cash flow[57] Operational Strategies and Future Plans - The company is committed to improving operational efficiency and exploring new market opportunities to enhance future performance[5] - The group plans to issue convertible bonds of HKD 16.8 million and ordinary bonds of HKD 55 million to offset existing convertible loans of approximately HKD 72.3 million due on October 10, 2024[6] - The group plans to enhance the promotion of health products, particularly traditional Chinese medicine, in response to the increasing demand driven by an aging population in Hong Kong[62] - The group aims to expand online sales channels for health products, capitalizing on the trend towards online shopping since the COVID-19 outbreak[62] - The group is actively attracting corporate clients, successfully securing orders for high-margin health tea bags and nourishing products during the period[63] - The group will enhance its credit policies and risk management strategies to navigate the challenging lending environment[64] Investment and Market Conditions - The group plans to adjust its investment portfolio based on global economic conditions and investor sentiment to improve performance[65] - The investment in financial instruments recorded a segment loss of approximately HKD 6 million for the period, compared to a segment profit of approximately HKD 4 million in 2023, primarily due to realized losses of approximately HKD 5 million[58] - The group reported a significant decrease in the fair value of its investments, with a loss of HKD 5,431 thousand due to fair value changes during the period[58] Dividends and Shareholder Information - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with no dividend declared for the same period in 2023[25] - The average number of ordinary shares used to calculate basic and diluted loss per share remained at 770,480,836 for both periods ended June 30, 2024, and June 30, 2023[26] - Shareholders' equity decreased from approximately HKD 4 million to a net liability position of approximately HKD 24 million due to operating losses during the period[67]

Ownership Stakes - China Healthwise Holdings Limited holds a 0.62% stake in Huanxi Media Group Limited as of December 31, 2023[1] - The company has a 3.95% ownership in Yuantong Port Development Limited as of December 31, 2023[1] - China Healthwise Holdings Limited owns a 0.19% share in Yunfeng Financial Group Limited as of December 31, 2023[1]

Financial Performance - For the year ended December 31, 2023, the Group's turnover increased by approximately 3% to approximately HK$146 million, compared to approximately HK$142 million for the year ended December 31, 2022[14]. - The gross profit margin for the Reporting Year was approximately 41%, compared to approximately 37% in the Corresponding Year[15]. - The overall loss attributable to owners of the Company was approximately HK$135 million, compared to HK$54 million in the Corresponding Year[15]. - Revenue for the year ended 31 December 2023 was approximately HK$146 million, a 3% increase from approximately HK$142 million in FY22, driven by improved performance in the investment financial instruments and traditional Chinese medicine segments[80]. - The Group recorded a loss attributable to shareholders of approximately HK$135 million in the Reporting Year, compared to approximately HK$54 million in FY22[87][90]. Revenue Segmentation - Revenue from the Chinese health product segment increased from approximately HK$128 million in FY22 to approximately HK$130 million in the Reporting Year[20]. - The Chinese herbal health products segment generated revenue of approximately HK$130 million in the reporting year, an increase from HK$128 million in FY22, with segment profit rising to approximately HK$3 million from HK$2 million in FY22[26]. - Revenue from the money lending segment decreased from approximately HK$15 million in FY22 to approximately HK$11 million in the Reporting Year[20]. - Revenue from the investment in financial instruments improved from a loss of approximately HK$1 million in FY22 to a gain of approximately HK$6 million in FY23[75]. Impairment and Losses - Impairment loss recognized for loan receivables increased from approximately HK$25 million in FY22 to approximately HK$107 million in FY23[21]. - The increase in segment loss was mainly due to an increase of approximately HK$82 million in expected credit loss (ECL) allowance, attributed to loan receivables totaling HK$124 million being reclassified to stage 3 (credit-impaired) during the year[29]. - The total allowance for ECL on loan receivables was approximately HK$294 million, an increase of approximately HK$107 million compared to HK$187 million in FY22[36]. - Impairment loss under the expected credit loss model increased significantly to approximately HK$107 million for the Reporting Year, compared to approximately HK$25 million in FY22, mainly due to the reclassification of 5 loan receivables to stage 3 (credit-impaired)[86][90]. Cash Flow and Assets - As of December 31, 2023, the Group's cash and bank balances were approximately HK$14 million, down from approximately HK$17 million as of December 31, 2022[69]. - Total current assets were approximately HK$140 million, while total current liabilities were approximately HK$143 million, resulting in a current ratio of approximately 0.98[115][116]. - Shareholders' funds decreased significantly from approximately HK$139 million as of December 31, 2022, to approximately HK$4 million as of December 31, 2023, primarily due to operating losses[115][116]. - The value of inventories increased by approximately 2% from approximately HK$55 million as at 31 December 2022 to approximately HK$56 million as at 31 December 2023, with inventory turnover days slightly decreasing to 236 days[100]. Corporate Governance - The Board is committed to high standards of corporate governance, ensuring compliance with all code provisions throughout the year ended December 31, 2023[144]. - The Company has established three committees: Audit, Remuneration, and Nomination, each with defined terms of reference[182]. - The Board comprises six Executive Directors and three Independent Non-executive Directors, with no relationships among members[166]. - All independent non-executive directors have confirmed their independence in accordance with Rule 3.13 of the Listing Rules for the year ended December 31, 2023[187]. Strategic Initiatives - The Group aims to diversify revenue sources through investments and acquisitions of promising businesses or projects[67]. - The Group plans to enhance online sales channels, particularly through platforms like "HKTVmall," which has contributed stable turnover during FY23[55]. - The Group aims to optimize operations using technology and data, including the potential implementation of a Customer Relationship Management System (CRM)[57]. - The Group will participate in shopping promotions and consider live commerce platforms to expand its customer base[57]. Market Outlook - The retail market in Hong Kong is expected to benefit from the full resumption of normal travel between Hong Kong and Mainland China, positively impacting sales[55]. - The demand for health care products, especially Chinese medicine, is expected to grow due to increasing health awareness and an aging population in Hong Kong[54].

Financial Performance - For the fiscal year ending December 31, 2023, China Healthwise Holdings Limited reported total revenue of HKD 146,317,000, an increase of 3% from HKD 142,058,000 in the previous year[2]. - The gross profit for the same period was HKD 60,294,000, representing a growth of 13.5% compared to HKD 53,270,000 in 2022[2]. - The company incurred a net loss of HKD 134,558,000 for the year, which is a significant increase from the net loss of HKD 54,274,000 in the prior year, reflecting a rise of 147%[3]. - The basic and diluted loss per share was HKD 17.46, compared to HKD 7.04 in the previous year, indicating a deterioration in earnings performance[3]. - Total comprehensive loss for the year amounted to HKD 134,251,000, up from HKD 54,415,000 in 2022, marking an increase of 147%[3]. - The company reported a pre-tax loss of HKD 118,243,000, compared to a loss of HKD 45,883,000 in the previous year, indicating a deterioration in financial performance[25]. - The net loss for the fiscal year ending December 31, 2023, was approximately HKD 135.5 million, compared to a loss of HKD 54 million in the previous fiscal year[50]. - The group recorded a loss attributable to shareholders of approximately HKD 135 million, compared to about HKD 54 million in the fiscal year 2022[71]. Assets and Liabilities - The company's total assets decreased to HKD 139,655,000 from HKD 275,017,000 in the previous year, indicating a decline of 49%[5]. - Current liabilities increased to HKD 142,953,000, up from HKD 74,756,000, reflecting an increase of 91%[5]. - The group's total equity as of December 31, 2023, was HKD 4.398 million, a significant decrease from HKD 138.649 million in 2022[10]. - Total liabilities increased to HKD 149,010,000 from HKD 145,272,000, showing a rise in financial obligations[26]. - The total non-current liabilities decreased from HKD 74.254 million in 2022 to HKD 2.319 million in 2023, indicating a significant reduction[10]. - The asset-to-liability ratio was approximately 25.25% as of December 31, 2023, compared to 0.73% as of December 31, 2022[81]. Cash Flow and Financial Condition - Cash and cash equivalents decreased to HKD 14,421,000 from HKD 16,850,000, a decline of 14.4%[5]. - The group plans to actively collect receivables to improve cash flow and financial condition[10]. - The board believes that the cash flow generated from operations will be sufficient to meet the business's funding needs and repay outstanding debts[10]. - The group’s cash and bank balances decreased to approximately HKD 14 million as of December 31, 2023, down from HKD 17 million as of December 31, 2022[81]. Revenue Segments - The revenue from the Chinese medicine health products segment was a significant contributor to the overall income, with no inter-segment sales reported[23]. - The lending business segment generated revenue of HKD 10,656 thousand, down from HKD 14,628 thousand in the previous year, reflecting a decrease[22]. - The investment financial instruments segment reported a revenue of HKD 6,138 thousand, compared to a loss of HKD 945 thousand in the previous year, indicating a recovery[22]. - The Chinese medicine health products segment generated revenue of approximately HKD 130 million, up from about HKD 128 million in the previous fiscal year, contributing a segment profit of approximately HKD 3 million[53]. - The investment financial instruments segment's revenue improved from a loss of approximately HKD 1 million in the fiscal year 2022 to a gain of approximately HKD 6 million in the reporting year[66]. Impairment and Credit Losses - The company reported a significant impairment loss of HKD 107,469,000 related to expected credit losses, compared to HKD 24,784,000 in the previous year[2]. - The expected credit loss provision increased by approximately HKD 82 million due to reclassification of receivables to Stage 3 (credit impaired) during the fiscal year[56]. - The expected credit loss provision for receivables increased to approximately HKD 294 million, up from HKD 187 million in 2022, representing an increase of about HKD 107 million[61]. - The carrying value of receivables from lending operations was HKD 311,313 thousand for the year ended December 31, 2023, down from HKD 320,800 thousand in 2022, with expected credit loss provisions of HKD (186,749) thousand in 2023 compared to HKD (294,218) thousand in 2022[40]. Cost Management - The company is implementing cost-saving measures to control administrative expenses and improve cash flow[10]. - Employee costs, including director remuneration, totaled HKD 42,418,000, indicating a rise in personnel expenses[28]. - The company’s general and administrative expenses were approximately HKD 38 million for the fiscal year ending December 31, 2023, unchanged from the previous fiscal year[70]. - The company incurred interest expenses of HKD 8,993,000, which includes HKD 5,533,000 related to unallocated costs[28]. Governance and Compliance - The company has adhered to all corporate governance guidelines as of December 31, 2023[83]. - The Audit Committee has reviewed the accounting principles and policies adopted by the group for the fiscal year ending December 31, 2023[87]. - There were no purchases, redemptions, or sales of any listed securities by the company or its subsidiaries during the fiscal year ending December 31, 2023[85]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[25]. - The overall financial outlook remains cautious due to the significant losses reported and the need for strategic adjustments moving forward[25]. - The group plans to enhance the promotion of health products, particularly traditional Chinese medicine, due to increasing demand driven by an aging population in Hong Kong[73]. - The online sales channel for traditional Chinese health products is expected to contribute stable revenue through platforms like "HKTVmall" in the fiscal year 2023[74].

Financial Performance - For the fiscal year ending December 31, 2023, the company reported total revenue of HKD 146,317,000, representing an increase of 3.0% from HKD 142,058,000 in the previous year[2]. - The gross profit for the year was HKD 60,294,000, up from HKD 53,270,000, indicating a growth of approximately 13.8%[2]. - The net loss for the year was HKD 134,558,000, compared to a net loss of HKD 54,274,000 in the previous year, reflecting an increase in losses of 147.5%[3]. - The company reported a basic and diluted loss per share of HKD 17.46, compared to HKD 7.04 in the previous year, indicating a significant increase in loss per share[3]. - Total comprehensive loss for the year was HKD 134,251,000, compared to HKD 54,415,000 in the previous year, marking an increase of 147.5%[3]. - The company reported a pre-tax loss of HKD 118,243,000 for the year, compared to a loss of HKD 45,883,000 in the previous year, indicating a significant increase in losses[25]. - The group recorded a loss attributable to shareholders of approximately HKD 135 million, compared to about HKD 54 million in the fiscal year 2022[71]. Assets and Liabilities - The company’s total assets as of December 31, 2023, were HKD 139,655,000, down from HKD 275,017,000 in the previous year, indicating a decrease of 49.3%[5]. - The company’s total liabilities decreased to HKD 142,953,000 from HKD 74,756,000, reflecting an increase of 90.9%[5]. - The total equity as of December 31, 2023, was HKD 4.398 million, a significant decrease from HKD 138.649 million in 2022[10]. - Total assets as of December 31, 2023, amounted to HKD 149,670,000, down from HKD 287,659,000 in the previous year, reflecting a decrease of approximately 48%[26]. - Total liabilities decreased to HKD 145,272,000 from HKD 149,010,000, showing a reduction of about 2%[26]. - The group’s net non-current liabilities decreased from HKD 74.254 million in 2022 to HKD 2.319 million in 2023[10]. Cash Flow and Financial Condition - The company reported a cash and cash equivalents balance of HKD 14,421,000, down from HKD 16,850,000, a decrease of 14.4%[5]. - The group plans to actively collect receivables to improve operating cash flow and financial condition[10]. - The company believes that the cash flow generated from operations will be sufficient to meet business funding needs and repay outstanding debts[10]. - The group is reviewing its investments and considering liquidating certain financial assets to enhance cash flow[10]. - The group’s cash and bank balances were approximately HKD 14 million as of December 31, 2023, down from HKD 17 million as of December 31, 2022[81]. Revenue Segments - The revenue from the Chinese medicine health products segment was a significant contributor to the overall income, with no inter-segment sales reported[23]. - The company has three operating segments: Chinese medicine health products, lending business, and investment financial instruments, each requiring different business strategies[23]. - The lending business segment generated revenue of HKD 10,656 thousand, down from HKD 14,628 thousand in the previous year, reflecting a decrease[22]. - The investment financial instruments segment reported a revenue of HKD 6,138 thousand, compared to a loss of HKD 945 thousand in the previous year, showing improvement[22]. - The Chinese medicine health products segment generated revenue of approximately HKD 130 million, up from about HKD 128 million in the previous fiscal year[53]. Impairment and Credit Losses - The company reported a net impairment loss on receivables of HKD 107,469,000, indicating significant credit risk exposure[28]. - The expected credit loss provision increased to approximately HKD 294 million, up by about HKD 107 million from HKD 187 million in 2022[61]. - The company recognized a significant impairment loss of HKD 107,469 thousand on receivables for the year ended December 31, 2023, compared to HKD 24,784 thousand in 2022[41]. - The expected credit loss model's impairment loss increased to approximately HKD 107 million for the reporting year, compared to about HKD 25 million in the fiscal year 2022[71]. Cost Management - The company’s operating expenses, including selling and administrative expenses, totaled HKD 65,403,000, slightly down from HKD 66,872,000, showing a decrease of 2.2%[2]. - The group has implemented cost-saving measures to control administrative costs and improve cash flow[10]. - Sales and distribution expenses decreased to approximately HKD 28 million, a reduction of about 3% compared to HKD 29 million in the corresponding year[70]. - The cost of goods sold decreased by approximately 3%, amounting to about HKD 86 million in the current fiscal year compared to HKD 89 million in the previous fiscal year[67]. Future Outlook and Strategy - The company plans to focus on expanding its market presence and developing new products in the upcoming fiscal year[25]. - The group plans to enhance online sales channels for traditional Chinese medicine health products, contributing stable revenue through platforms like "HKTVmall" in the fiscal year 2023[74]. - The group aims to attract corporate clients, successfully drawing several charitable organizations to order high-margin health products in the fiscal year 2023[74]. - The group is actively seeking to diversify revenue sources through investments or acquisitions of promising businesses or projects[79]. Governance and Compliance - The company has adhered to all corporate governance rules as of December 31, 2023[83]. - The Audit Committee has reviewed the accounting principles and policies adopted by the group for the fiscal year ending December 31, 2023[87]. - The company has published its performance announcement on the Hong Kong Stock Exchange and its own website[88].

Financial Performance - Revenue for the six months ended 30 June 2023 was HK$80,826,000, representing an increase of 6.7% compared to HK$76,270,000 for the same period in 2022[3]. - Gross profit for the period was HK$33,653,000, up from HK$26,528,000, indicating a gross profit margin improvement[3]. - Loss for the period attributable to owners of the Company was HK$31,862,000, compared to a loss of HK$15,176,000 in the previous year, reflecting a significant increase in losses[4]. - Total comprehensive loss for the period was HK$31,559,000, compared to HK$15,337,000 for the same period in 2022[4]. - The Company reported a basic and diluted loss per share of 1.97 cents, compared to 4.14 cents in the previous year, indicating a reduction in loss per share despite overall losses[4]. - The loss attributable to owners of the Company was approximately HK$32 million, compared to a loss of approximately HK$15 million in the corresponding period[97]. - Loss before income tax for the six months ended June 30, 2023, was HK$31,862,000, compared to a loss of HK$15,176,000 in the same period of 2022, reflecting a significant increase in losses[50]. Cash Flow and Liquidity - Net cash inflow from operating activities was HK$304,000, a recovery from a net outflow of HK$26,204,000 in the prior year[11]. - Cash and cash equivalents at the end of the period decreased to HK$8,843,000 from HK$28,753,000 at the end of the previous period[11]. - Current liabilities decreased to HK$48,715,000 from HK$74,756,000, indicating improved liquidity management[7]. - The current ratio improved to approximately 4.5 as of June 30, 2023, compared to approximately 3.7 as of December 31, 2022[158]. Assets and Liabilities - Total segment assets decreased to HK$233,622,000 as of June 30, 2023, down from HK$287,158,000 at the end of 2022, representing a decline of 18.7%[37]. - Total liabilities decreased to HK$126,851,000 as of June 30, 2023, compared to HK$149,010,000 at the end of 2022, a reduction of 14.8%[37]. - The Company’s equity reserve remained stable at HK$19,835,000 as of June 30, 2023, unchanged from January 1, 2023[13]. - The total accumulated allowance for ECL as of June 30, 2023, was based on a valuation prepared by an independent professional valuer, in accordance with HKFRS 9 Financial Instruments[131]. Revenue Streams - The Company is primarily engaged in the sale of Chinese health products, money lending business, and investment in financial instruments, indicating a diversified revenue stream[26]. - Revenue from contracts with customers for the six months ended June 30, 2023, was HK$80,826,000, a 6.7% increase from HK$76,270,000 in the same period of 2022[27]. - Revenue from trading of Chinese health products increased to HK$70,259,000, up from HK$69,134,000, reflecting a growth of 1.6%[27]. - The Chinese health products business contributed approximately HK$70 million in revenue, representing an increase of approximately 1% from approximately HK$69 million in the corresponding period[99]. Impairment and Credit Losses - Impairment loss on loan receivables under the expected credit loss model was HK$28,334,000, significantly higher than HK$2,547,000 in the previous period[27]. - The allowance for expected credit losses (ECL) rose to HK$215,084,000 as of June 30, 2023, from HK$186,749,000 at December 31, 2022, indicating an increase of 15.2%[55]. - The impairment loss in respect of loan receivables increased from approximately HK$3 million in the corresponding period to approximately HK$28 million in the Period[101]. - The allowance for ECL for loan receivables classified under stage 3 (credit impaired) increased from approximately HK$170 million as of December 31, 2022, to approximately HK$195 million as of June 30, 2023, primarily due to overdue interest and principal on a stage 3 loan for more than three months[118]. Operational Strategies and Future Outlook - The Company has not provided specific guidance for future performance but continues to focus on operational efficiency and cost management strategies[5]. - The Group plans to strengthen the promotion of health care products, including cordyceps sinensis and ginseng, in response to the growing demand for health products in Hong Kong[143]. - Following the resumption of normal travel between Hong Kong and Mainland China, the Group anticipates a positive impact on the retail market and will continue to develop online sales channels for Chinese health products[144]. - The retail industry faces challenges due to inflation and rising costs, but the Group aims to optimize operations using technology and data, including the potential implementation of a Customer Relationship Management System (CRM)[146]. Corporate Governance and Compliance - The Company has complied with all provisions of the Corporate Governance Code throughout the reporting period[193]. - The Audit Committee has reviewed the unaudited condensed interim financial statements for the six months ended June 30, 2023[195]. - The Company has adopted a code of conduct for securities transactions by Directors, confirming compliance throughout the accounting period[194].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 CHINA HEALTHWISE HOLDINGS LIMITED 中 國 智 能 健 康 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號：348） 截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 未 經 審 核 中 期 業 績 中國智能健康控股有限公司（「本公司」）董事會（「董事會」或「董事」）欣然公 佈本公司及其附屬公司（統稱「本集團」）截至二零二三年六月三十日止六 個月之未經審核簡明綜合業績，連同截至二零二二年六月三十日止六個 月 同 期 之 比 較 數 字。此 等 中 期 綜 合 財 務 報 表 均 未 經 審 核，惟 已 由 本 公 司 審核委員會審閱。 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 未經審核 截至 截至 二零二三年 二零二二年 六月三十日 六月三十日 止六個月 止六個月 附註 千港元 千港元 ...